Clinical-Based vs. Model-Based Adaptive Dosing Strategy: Retrospective Comparison in Real-World mRCC Patients Treated with Sunitinib

Different target exposures with sunitinib have been proposed in metastatic renal cell carcinoma (mRCC) patients, such as trough concentrations or AUCs. However, most of the time, rather than therapeutic drug monitoring (TDM), clinical evidence is preferred to tailor dosing, i.e., by reducing the dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Ferrer, Florent, Chauvin, Jonathan, DeVictor, Bénédicte, Lacarelle, Bruno, Deville, Jean-Laurent, Ciccolini, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224810/
https://www.ncbi.nlm.nih.gov/pubmed/34073681
http://dx.doi.org/10.3390/ph14060494

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8224810/
https://www.ncbi.nlm.nih.gov/pubmed/34073681
http://dx.doi.org/10.3390/ph14060494

Ejemplares similares